 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2013;6(5):367-371
Original Article
Unresectable hepatocellular carcinoma treated with transarterial
chemoembolization: clinical data from a single teaching hospital
Youhui Wang, Yanping Shen
Department of Cancer Chemotherapy and Radiotherapy, Yinzhou People’s Hospital Affiliated to Ningbo University School of Medicine,
Ningbo, Zhejiang 315040, China
Received April 4, 2013; Accepted May 7, 2013; Epub May 22, 2013; Published June 1, 2013
Abstract: The aim of this study is to evaluate the survival rates of patients with unresectable hepatocellular carcinoma (HCC) following
transarterial chemoembolization (TACE) performed in a single teaching hospital. This study retrospectively assessed the electronic
medical records of 217 patients in whom HCC was newly diagnosed from January 2009 to February 2013 at a single medical center.
Hepatic artery infusion chemotherapy was performed using one drug or combinations of oxaliplatin, fluorouracil and doxorubicin. The
primary endpoint of the study was overall survival (OS). Survival rates were calculated using Kaplan-Meier method. A total of 217 HCC
patients (173 men and 44 women; mean age, 56.3 years; age range, 36.1-84.3 years) were treated with TACE in a single center. The
overall survival rates at 1 and 2 years were 64% and 40%, respectively. The overall median survival time from the start of TACE
treatment was 13 months. Our results indicated that TACE is an effective minimally invasive therapy option for palliative treatment of
HCC patients. (IJCEM1304002).
Keywords: Chemoembolization, embolization, hepatocellular carcinoma, transarterial chemoembolization
Address correspondence to: Dr. Yanping Shen, Department of Cancer Chemotherapy and Radiotherapy, Yinzhou People’s Hospital
Affiliated to Ningbo University School of Medicine, 251, Baizhang Eastern Road, Ningbo, Zhejiang 315040, China. Tel: +86-574-
87017563 or +86-13505745568; Fax: +86-574-87017367; E-mail: dr.shenyanping@yahoo.com.cn
Original Article
Unresectable hepatocellular carcinoma treated with transarterial
chemoembolization: clinical data from a single teaching hospital
Youhui Wang, Yanping Shen
Department of Cancer Chemotherapy and Radiotherapy, Yinzhou People’s Hospital Affiliated to Ningbo University School of Medicine,
Ningbo, Zhejiang 315040, China
Received April 4, 2013; Accepted May 7, 2013; Epub May 22, 2013; Published June 1, 2013
Abstract: The aim of this study is to evaluate the survival rates of patients with unresectable hepatocellular carcinoma (HCC) following
transarterial chemoembolization (TACE) performed in a single teaching hospital. This study retrospectively assessed the electronic
medical records of 217 patients in whom HCC was newly diagnosed from January 2009 to February 2013 at a single medical center.
Hepatic artery infusion chemotherapy was performed using one drug or combinations of oxaliplatin, fluorouracil and doxorubicin. The
primary endpoint of the study was overall survival (OS). Survival rates were calculated using Kaplan-Meier method. A total of 217 HCC
patients (173 men and 44 women; mean age, 56.3 years; age range, 36.1-84.3 years) were treated with TACE in a single center. The
overall survival rates at 1 and 2 years were 64% and 40%, respectively. The overall median survival time from the start of TACE
treatment was 13 months. Our results indicated that TACE is an effective minimally invasive therapy option for palliative treatment of
HCC patients. (IJCEM1304002).
Keywords: Chemoembolization, embolization, hepatocellular carcinoma, transarterial chemoembolization
Address correspondence to: Dr. Yanping Shen, Department of Cancer Chemotherapy and Radiotherapy, Yinzhou People’s Hospital
Affiliated to Ningbo University School of Medicine, 251, Baizhang Eastern Road, Ningbo, Zhejiang 315040, China. Tel: +86-574-
87017563 or +86-13505745568; Fax: +86-574-87017367; E-mail: dr.shenyanping@yahoo.com.cn
